Caplight Directory>Companies>Cimeio Therapeutics-preview>Cimeio


Cimeio Therapeutics

Cimeio Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.cimeio.com

Last Round

Series A

Apr 13, 2022

Total Funding Raised

$50M

Momentum Score

50 /100

Company Overview

Cimeio is a biotechnology company specializing in immunotherapy technology that aims to treat leukemic tumors, autoimmune diseases, and enhance bone marrow transplants and stem cell replacement through innovative gene-editing and cell shielding techniques.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell shieldingepitope editingSCIP platformcell therapyimmunotherapyHSC transplantstem cell transplantgene editingchemo-free transplantpaired immunotherapiesCAR-T therapyhematologic malignanciesautoimmune disease therapyantibody-drug conjugatesADCsT-cell engagers

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cimeio Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cimeio Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AApr 13, 2022
View all Funding Rounds

Cimeio Therapeutics Investors

Notable investors and investment history

InvestorRounds
Versant VenturesSeries A
BaseLaunchSeries A
University of BaselSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 246% MoM to 2.3K.

View all signals

Cimeio Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cimeio Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cimeio Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range16
Year Founded2020
Last FundingApr 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.